

GLAXOSMITHKLINE ORD GBP0.25

ISIN: **GB0009252882** WKN: **0925288**

Overview

2020/04/21 17:36:26

Price

21.50 CHF

Difference  -2.27% (-0.50)

General attributes

ISIN GB0009252882

Symbol GSK

Exchange SIX Swiss Exchange

Currency CHF

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 76,892 EUR

Benchmark FTSE 100

Market data

Bid (Bid size) 21.00 CHF (31)

Ask (Ask size) 19.98 CHF (1)

Open 21.50 CHF

High 21.50 CHF

Low 21.50 CHF

Close (prev. day) 22.00 CHF

VWAP 17.14 CHF

Volume (pcs) -

Trading volume -

Number of trades 1

Last size -

Futures and Options

Related Futures 41

Related Options -

PDF Downloads

Annual report: GLAXOSMITHKLINE
ORD GBP0.25 











5Y



Information about previous performance does not guarantee future performance.

Source: FactSet

Recent research

on instrument		on sector	
Date		Headline	Download
2021/04/08		Global Equity Ratings	
2021/04/08		Aktienempfehlungen Global	
2021/04/01		Global Equity Ratings	
2021/04/01		Aktienempfehlungen Global	
2021/03/03		Global Equity Ratings	

Details

2020/04/21 17:36:26

Price

21.50 CHF

Difference  -2.27% (-0.50)

General attributes

ISIN GB0009252882

Symbol GSK

Exchange SIX Swiss Exchange

Currency CHF

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 76,892 EUR

Benchmark FTSE 100

Market data

Bid (Bid size) 21.00 CHF (31)

Ask (Ask size) 19.98 CHF (1)

Open 21.50 CHF

High 21.50 CHF

Low 21.50 CHF

Close (prev. day) 22.00 CHF

VWAP 17.14 CHF

Volume (pcs) -

Trading volume -

Number of trades 1

Last size -

Performance and Risk

	6M	1Y	3Y
Perf (%)	-	-	-
Perf (abs.)	-	-	-
Beta	0.77	0.73	0.69
Volatility	-	10.01	18.73

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days Ø volume 5 days (pcs.)	- CHF (2,961,709)
Ø price 30 days Ø volume 30 days (pcs.)	2.90 CHF (1,595,658)
Ø price 100 days Ø volume 100 days (pcs.)	8.14 CHF (970,754)
Ø price 250 days Ø volume 250 days (pcs.)	14.95 CHF (425,438)
YTD High date	- CHF (-)
YTD Low date	- CHF (-)
52 Weeks High date	22.00 CHF (2020/04/20)
52 Weeks Low date	21.50 CHF (2020/04/21)

All listings for GLAXOSMITHKLINE ORD GBP0.25

Exchange 	Date	Time	Price	Trading volume (mio.)	Number of trades
Xetra	2021/04/20	17:35	15.54 EUR	2.60	448
Tradegate	2021/04/20	22:26	15.70 EUR	1.22	170
Stuttgart	2021/04/20	13:21	15.66 EUR	0.46	8
SIX Swiss Exchange	2020/04/21	17:36	21.50 CHF	0.00	1
Munich	2021/04/20	08:00	15.74 EUR	0.00	2

	20					
London Stock Exchange	2021/04/20	17:35	1,325.20 GBp	10,277.31		14,117
Hanover	2021/04/20	08:02	15.74 EUR	0.00		2
Hamburg	2021/04/20	16:58	15.60 EUR	0.03		4
Frankfurt	2021/04/20	17:06	15.60 EUR	0.11		15
FINRA other OTC Issues	2021/04/20	16:31	18.38 USD	0.08		10
Duesseldorf	2021/04/20	19:31	15.52 EUR	0.02		23
Berlin	2021/04/20	12:50	15.68 EUR	0.03		4

Company profile

Company Logo



Contact Details

GLAXOSMITHKLINE PLC

--

980 Great West Road - TW8 9GS Middlesex

Telefon: 44-20-8047-5000

Fax: 44-20-8047-7807

E-mail: -

PDF Downloads

Annual report: GLAXOSMITHKLINE
ORD GBP0.25



Company Profile

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Members of Management Board

Emma Walmsley	Chairman of Managing Board
Christopher Corsico	Member of Executive Committee
Jon Ellis	Member of Executive Committee
Lon Cardon	Member of Executive Committee
Neil Barnes	Member of Executive Committee
Rab Prinjha	Member of Executive Committee
Amy Altshul	Member of Executive Committee
Brian McNamara	Member of Executive Committee
David Redfern	Member of Executive Committee
Deborah Waterhouse	Member of Executive Committee
Diana Conrad	Member of Executive Committee
James Ford	Member of Executive Committee
Karenann Terrell	Member of Executive

Board of directors

Jonathan Symonds	Chairman of Supervisory Board
Hal Barron	Member of Supervisory Board
Jesse Goodman	Member of Supervisory Board
Laurie Glimcher	Member of Supervisory Board
Charles Bancroft	Member of Supervisory Board
Iain Mackay	Member of Supervisory Board
Judy Lewent	Member of Supervisory Board
Lynn Elsenhans	Member of Supervisory Board
Manvinder Singh Banga	Member of Supervisory Board
Urs Rohner	Member of Supervisory Board
Vivienne Cox	Member of Supervisory Board

	Committee
Kevin Sin	Member of Executive Committee
Luke Miels	Member of Executive Committee
Marc Jones	Member of Executive Committee
María Cristina Henríquez de Luna Basagoiti	Member of Executive Committee
Maya Martinez-Davis	Member of Executive Committee
Nick Hirons	Member of Executive Committee
Philip Thomson	Member of Executive Committee